Logo_CBS-横版-原色(RGB)
Autosampler with capped vials loaded into an analyzer for biologics developability assessment

Developability Assessment for Biologics



Developability assessment identifies chemical and biophysical risks in a biologic candidate before they become manufacturing, formulation or clinical problems. Crystal Bio Solutions, part of Crystal Group, runs chemical and biophysical developability panels for antibodies, antibody fragments and VHHs, multispecifics and other proteins in our biologics CMC analytical laboratory in Natick, Massachusetts, with results compared against predefined targets to support candidate selection.


CBS orange-blue banner-1
pH and Time Stress Panel Purity and variants followed across several pH conditions and time points by SEC, HIC, cIEF, non-reduced and reduced CE-SDS, and appearance. Chemical Liability Mapping Intact mass and time-course peptide mapping at the intended formulation pH for Met and Trp oxidation, Asp isomerization, deamidation, clipping, terminal processing and glycosylation, including CDR hot spots. Thermal and Colloidal Stability Thermal onset by DSC, aggregation temperature, hydrodynamic radius and polydispersity by DLS, and self-interaction (kD) as an indicator of concentratability. High-Concentration Behavior Viscosity and opalescence at high concentration (for example 200 mg/mL) to flag risks for subcutaneous formulations. Interfacial and Process Stress Agitation stress, silicone oil compatibility and reduction sensitivity, monitored by turbidity and high molecular weight species. Hydrophobic Variant Follow-Up When HIC shows hydrophobic species, peaks are collected and re-analyzed by HIC, SEC and intact mass to distinguish conformational variants, non-covalent aggregates and covalent species.
CBS orange banner-1
Crystal Bio Solutions biologics CMC analytical laboratory in Natick, Massachusetts Where Developability Fits
  • Discovery: screening and initial developability and risk assessment to rank candidates
  • Lead selection: full chemical and biophysical panels against predefined targets
  • Preclinical development: pre-formulation, stability and serum stability
  • Transition to CMC: liabilities and methods carry forward into the IND analytical package

Finding a liability at this stage usually means choosing or engineering a different candidate. Finding it after manufacturing has started can mean reformulation or comparability work.

Related reading: HRMS in Biologics Characterization

Related Services

Biologics CMC Analytical Characterization, CMC analytical strategy and gap analysis for biologics. Extended Characterization by HRMS Intact mass, peptide mapping, PTMs, disulfides, glycans and charge variants. Biotransformation and In Vivo CQA Drug characterization in serum and other matrices after dosing. ADC Programs DAR, conjugation, payload stability and ADC bioanalysis.

Frequently Asked Questions

 

What is a developability assessment?

A developability assessment evaluates whether a biologic candidate can be manufactured, formulated, stored and delivered reliably. It measures chemical stability, such as oxidation and deamidation, and biophysical behavior, such as aggregation, thermal stability, self-interaction and viscosity, usually to compare candidates before one is selected.

 

When should developability be assessed?

During discovery and lead optimization, before a single candidate is selected. Problems found then can often be solved by choosing another candidate or changing the sequence, which costs much less than addressing them after manufacturing has started.

 

What is the difference between chemical and biophysical developability?

Chemical developability looks at covalent changes, such as oxidation, deamidation, isomerization and clipping, followed by SEC, HIC, cIEF, CE-SDS, intact mass and peptide mapping. Biophysical developability looks at physical behavior such as thermal stability, aggregation, self-interaction, viscosity, opalescence and response to agitation or interfaces.

 

Why study viscosity and opalescence at high concentration?

Many antibodies are given subcutaneously at high concentration. High viscosity makes manufacturing and injection difficult, and opalescence can indicate self-association. Measuring both early helps select candidates suited to the intended formulation.

 

What does kD tell you?

The diffusion interaction parameter (kD), measured by DLS, indicates whether molecules attract or repel each other in solution. Attractive self-interaction is associated with higher viscosity, opalescence and aggregation risk at high concentration.

 

Can developability panels be applied to VHHs, multispecifics and ADCs?

Yes. Panels are adapted to the format. For VHH-containing molecules, for example, peptide mapping focuses on known liability sites in the CDRs, such as methionine oxidation and aspartate isomerization.

 

Where does Crystal Bio Solutions perform developability work?

Developability assessment is performed in the CBS biologics CMC analytical laboratory in Natick, Massachusetts.

 

Have a Question?

Connect with our experts and get started on your project today.